{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:24:39Z","timestamp":1777080279575,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.aprim.2021.102047","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T12:35:24Z","timestamp":1617453324000},"page":"102047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adecuaci\u00f3n de la seguridad del metamizol y agranulocitosis"],"prefix":"10.1016","volume":"53","author":[{"given":"Cristina","family":"Garcia del Campo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Murcia Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inocencia","family":"Martinez-Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Palop Larrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2021.102047_bib0170","series-title":"Seguridad y medicamentos. Reacciones adversas a los medicamentos: m\u00e9todos y problemas de la farmacovigilancia.","first-page":"45","article-title":"Historia de una reacci\u00f3n adversa: la agranulocitosis por dipirona","author":"Vallv\u00e9","year":"1987"},{"key":"10.1016\/j.aprim.2021.102047_bib0175","first-page":"81","article-title":"Chronic use of metamizole: Not so safe after all?","volume":"75","author":"Vuik","year":"2017","journal-title":"Neth J Med."},{"key":"10.1016\/j.aprim.2021.102047_bib0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00228-002-0465-2","article-title":"Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole)","volume":"58","author":"Hedenmalm","year":"2002","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.aprim.2021.102047_bib0185","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00228-015-1895-y","article-title":"Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012","volume":"71","author":"Stammschulte","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.aprim.2021.102047_bib0190","unstructured":"European Medicines Agency (EMA). Metamizole containing medicinal products [consultado 18 Jun 2020]. Disponible en: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/metamizole-containing-medicinal-products"},{"key":"10.1016\/j.aprim.2021.102047_bib0195","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Metamizol y riesgo de agranulocitosis. Informaci\u00f3n para profesionales sanitarios. Nota informativa. Fecha de publicaci\u00f3n: 30 de octubre de 2018. Referencia: MUH (FV), 15\/2018. Disponible en: https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2018\/docs\/NI_MUH_FV-15-2018-metamizol-agranulocitosis.pdf."},{"key":"10.1016\/j.aprim.2021.102047_bib0200","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Utilizaci\u00f3n de medicamentos analg\u00e9sicos no opioides en Espa\u00f1a durante el periodo 2010-2018 [consultado18 Jun 2020]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/observatorio-de-uso-de-medicamentos\/utilizacion-de-medicamentos-analgesicos-no-opioides-en-espana-durante-el-periodo-2010-2018\/"},{"key":"10.1016\/j.aprim.2021.102047_bib0205","unstructured":"Real Decreto 577\/2013, de 26 de julio, por el que se regula la farmacovigilancia de medicamentos de uso humano. BOE n\u00fam. 179, de 27 de julio del 2013."},{"issue":"10.117","key":"10.1016\/j.aprim.2021.102047_bib0210","first-page":"8","article-title":"Britons die after taking Spanish painkiller","author":"Ungoed-Thomas","year":"2018","journal-title":"The Sunday Times (London)."},{"issue":"Suppl. 2","key":"10.1016\/j.aprim.2021.102047_bib0215","first-page":"8","article-title":"Retirada de medicamentos por motivos de seguridad en Espa\u00f1a (1999-2007)","volume":"113","author":"Iba\u00f1ez","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.aprim.2021.102047_bib0220","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.medcli.2018.02.018","article-title":"Restricciones de la nitrofuranto\u00edna: luces y sombras","volume":"151","author":"Mart\u00ednez-Macias","year":"2018","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.aprim.2021.102047_bib0225","unstructured":"Ficha t\u00e9cnica: contenido e importancia en la prescripci\u00f3n. Informaci\u00f3n terap\u00e9utica del Sistema Nacional de Salud. 2006, volumen 30, N.\u00b0 4\/2006. p. 114-116."},{"key":"10.1016\/j.aprim.2021.102047_bib0230","series-title":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos","year":"2019"},{"key":"10.1016\/j.aprim.2021.102047_bib0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1977213247","article-title":"Toward the operational identification of adverse drug reactions","volume":"21","author":"Karch","year":"1977","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.aprim.2021.102047_bib0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/pds.2630010207","article-title":"Causality classification at pharmacovigilance centres in the European Community","volume":"1","author":"Meyboom","year":"1992","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.aprim.2021.102047_bib0245","series-title":"Principios de epidemiolog\u00eda del medicamento","first-page":"147","article-title":"La notificaci\u00f3n espont\u00e1nea de reacciones adversas a medicamentos","author":"Capell\u00e0","year":"1993"},{"key":"10.1016\/j.aprim.2021.102047_bib0250","doi-asserted-by":"crossref","first-page":"w14438","DOI":"10.4414\/smw.2017.14438","article-title":"Leucopenia associated with metamizole: A case-control study","volume":"147","author":"Blaser","year":"2017","journal-title":"Swiss Med Wkly."},{"key":"10.1016\/j.aprim.2021.102047_bib0255","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/EJA.0000000000000275","article-title":"Use of metamizole in children and the risk of agranulocytosis. Is the benefit worth the risk?","volume":"32","author":"Rollason","year":"2015","journal-title":"Eur J Anaesthesiol."},{"key":"10.1016\/j.aprim.2021.102047_bib0260","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pds.697","article-title":"Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis","volume":"11","author":"B\u00e4ckstr\u00f6m","year":"2002","journal-title":"Pharmacoepidemiol Drug Safe."},{"key":"10.1016\/j.aprim.2021.102047_bib0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00008571-199602000-00005","article-title":"Genetic factors and risk of agranulocytosis from metamizol","volume":"6","author":"Vlahov","year":"1996","journal-title":"Pharmacogenetics."},{"key":"10.1016\/j.aprim.2021.102047_bib0270","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0014-2565(09)71310-4","article-title":"Agranulocitosis por metamizol: un potencial problema en la poblaci\u00f3n brit\u00e1nica","volume":"209","author":"M\u00e9rida Rodrigo","year":"2009","journal-title":"Rev Clin Esp."},{"key":"10.1016\/j.aprim.2021.102047_bib0275","unstructured":"Federaci\u00f3n Empresarial de Farmac\u00e9uticos Espa\u00f1oles. Observatorio del Medicamento. Enero 2019. Disponible en: https:\/\/www.actasanitaria.com\/wp-content\/uploads\/2019\/03\/Observatorio-del-Medicamento_enero19LP.pdf"},{"key":"10.1016\/j.aprim.2021.102047_bib0280","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-150-5-200903030-00108","article-title":"Controlling off-label medication use","volume":"150","author":"Gillck","year":"2009","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.aprim.2021.102047_bib0285","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-004-0836-y","article-title":"Agranulocytosis associated with dipyrone (metamizol)","volume":"60","author":"Iba\u00f1ez","year":"2005","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.aprim.2021.102047_bib0290","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.1986.03380130077032","article-title":"Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study","volume":"256","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.aprim.2021.102047_bib0295","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1001\/jama.1987.03390190068009","article-title":"Analgesic use. Agranulocytosis and aplastic anemia","volume":"257","author":"Van Dijke","year":"1987","journal-title":"JAMA."},{"key":"10.1016\/j.aprim.2021.102047_bib0300","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(84)91966-4","article-title":"Agranulocytosis and pyrazolone","volume":"1","author":"Shapiro","year":"1984","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2021.102047_bib0305","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/FPC.0000000000000157","article-title":"Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis","volume":"25","author":"Garc\u00eda-Mart\u00edn","year":"2015","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.aprim.2021.102047_bib0310","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jcpt.12768","article-title":"Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity?","volume":"44","author":"Shah","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.aprim.2021.102047_bib0315","unstructured":"Real Decreto Legislativo 1\/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garant\u00edas y uso racional de los medicamentos y productos sanitarios. BOE 179, de 25 de julio del 2015."},{"key":"10.1016\/j.aprim.2021.102047_bib0320","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1157\/13085947","article-title":"Calidad de la publicaci\u00f3n de reacciones adversas a medicamentos en la secci\u00f3n de cartas al director de cuatro revistas espa\u00f1olas de Medicina Interna y Medicina General","volume":"37","author":"Sempere","year":"2006","journal-title":"Aten Primaria."},{"key":"10.1016\/j.aprim.2021.102047_bib0325","first-page":"665","article-title":"Under-reporting of adverse drug safety","volume":"14","author":"Hacell l","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.aprim.2021.102047_bib0330","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656721000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656721000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:59:55Z","timestamp":1759323595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656721000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0212656721000810"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2021.102047","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adecuaci\u00f3n de la seguridad del metamizol y agranulocitosis","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2021.102047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102047"}}